Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
about
Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.Management of obesity in the psychiatrist's office.Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.Obesity Prevention for Children with Developmental Disabilities.Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Cancer screening, prevention, and treatment in people with mental illness.Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordEffect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.A core outcome set for evaluating self-management interventions in people with comorbid diabetes and severe mental illness: study protocol for a modified Delphi study and systematic reviewModified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?Horizons in the Pharmacotherapy of Obesity.Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Outpatient metformin management of obese individuals with schizophreniaFixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.Learned lessons from patients who take clozapine: A case study.The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.Management of common adverse effects of antipsychotic medications
P2860
Q27692023-DA5A059B-F8FD-4C8C-A2DE-57BB3BFAAB44Q33915520-D8105AD4-F2DA-4872-A64E-512B62E5AA65Q34331847-DA7CB2A3-AFF6-49B5-B26F-56AF88B2E358Q34711543-87C04C1C-F9C9-41F8-A6E1-7106E203BB74Q36156730-A2E73795-61C3-48F9-9558-107A08BDFFA9Q36223890-A1C9FA60-087A-4983-B81F-71CC11F52979Q36240230-A8B9D09F-1065-46D8-B86C-43A9A470A3F9Q36377890-3FCCAF28-B5C7-46B3-B8E4-85C5451E4B30Q36665194-AD08743F-4381-4770-BCD1-AD022667E14AQ36921831-67CBCE25-6DCD-4366-B398-B9E21AF81D2FQ37633458-471A25C3-E099-4CAF-962B-6EF2DA60B8B6Q37642902-34511481-6AD4-436B-B9A4-5C2C3B35B48BQ37721268-A456EC79-1A55-4F26-823A-7041CFD13810Q38582461-70C75E0D-5724-47DA-A9C9-73440256CB6BQ38626655-B1B89267-70EF-470A-9D4C-B80DACA82700Q38737909-30C13868-850E-4FE9-A1D0-02F96D2A4ED5Q38815462-E5ECB5D5-5E44-4F87-9DD0-0A488B577A58Q38826206-014904BF-9883-46FA-B3C8-50BF5C2487F8Q42689867-A6E10EBA-D546-4486-8E53-AF64EC0AA9B1Q47133208-E2D72615-8C59-47CF-8F94-39A035D2B114Q47220544-44ABA7CF-065F-4297-A369-F8F17E1B6FFFQ47351095-ACEFA234-3B02-407B-B2C0-19ACFFFD3926Q47618856-389D3ABC-39C4-4ACE-B8A7-A648AB17C500Q53689686-E98647A5-28D8-423A-82B0-823D47B1EA50Q58760350-D343A38C-5DE1-42FE-B353-35656E6BDB11
P2860
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metformin for weight loss and ...... and schizoaffective disorder.
@en
Metformin for weight loss and ...... and schizoaffective disorder.
@nl
type
label
Metformin for weight loss and ...... and schizoaffective disorder.
@en
Metformin for weight loss and ...... and schizoaffective disorder.
@nl
prefLabel
Metformin for weight loss and ...... and schizoaffective disorder.
@en
Metformin for weight loss and ...... and schizoaffective disorder.
@nl
P2093
P2860
P921
P1476
Metformin for weight loss and ...... and schizoaffective disorder.
@en
P2093
Dawn D Stewart
Diane J Catellier
L Fredrik Jarskog
Lauren H Golden
Lisa Lavange
METS Investigators
Robert M Hamer
T Scott Stroup
P2860
P304
P356
10.1176/APPI.AJP.2013.12010127
P407
P577
2013-09-01T00:00:00Z